Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: mannitol; crospovidone; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; hypromellose; macrogol 400 - for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: mannitol; crospovidone; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; hypromellose; macrogol 400 - for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: mannitol; crospovidone; povidone; sodium lauryl sulfate; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; hypromellose; macrogol 400 - for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Kanada - engelska - Health Canada

pharmascience inc - irbesartan; hydrochlorothiazide - tablet - 150mg; 12.5mg - irbesartan 150mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Kanada - engelska - Health Canada

pharmascience inc - irbesartan; hydrochlorothiazide - tablet - 300mg; 12.5mg - irbesartan 300mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Kanada - engelska - Health Canada

pharmascience inc - irbesartan; hydrochlorothiazide - tablet - 300mg; 25mg - irbesartan 300mg; hydrochlorothiazide 25mg - angiotensin ii receptor antagonists